Royalty Pharma (RPRX) Stock Overview
Operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 2/6 |
RPRX Community Fair Values
Create NarrativeSee what 59 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Royalty Pharma plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$58.61 |
| 52 Week High | US$64.38 |
| 52 Week Low | US$34.63 |
| Beta | 0.43 |
| 1 Month Change | 0.017% |
| 3 Month Change | 8.00% |
| 1 Year Change | 61.19% |
| 3 Year Change | 108.35% |
| 5 Year Change | 52.23% |
| Change since IPO | 31.71% |
Recent News & Updates
Narrative Update • Sep 03
RPRX: Royalty Deals And Buybacks Will Support Future Defensive Cash Flows
Royalty Pharma's analyst price target has been revised from $59.25 to $64.75 as analysts factor in updated guidance, recent Q2 outcomes, and expectations that support higher assumed future P/E levels, despite adjustments to growth and margin assumptions. Analyst Commentary Recent Street research on Royalty Pharma reflects a generally constructive tone, with several firms lifting their price targets in response to updated guidance and Q2 outcomes.Seeking Alpha • Aug 26
Royalty Pharma: The Quiet Compounder The Market Is Still Mispricing
Summary Royalty Pharma demonstrates high-quality, cash-generative compounding with durable royalty growth and disciplined capital deployment, supporting a buy rating. RPRX's 2Q26 results highlight 14% Royalty Receipts growth, elite 95% margins, and $728 million operating cash flow, reinforcing the core compounder thesis. Management raised 2026 Portfolio Receipts guidance to $3.4–$3.5 billion, projecting 7–10% royalty growth despite headwinds like Promacta erosion and IRA-related pressure. Valuation remains attractive on cash flow multiples, with embedded pipeline optionality and forward catalysts such as the Cliramitug deal and strategic pipeline expansion. Read the full article on Seeking Alpha
Narrative Update • Aug 19
RPRX: Raised 2026 Guidance And Royalty Pipeline Will Support Long Term Upside
Royalty Pharma's analyst fair value estimate has shifted from $66.00 to $70.00. This reflects updated views from analysts who recently raised price targets in response to Q2 updates, revised 2026 guidance, and perceived strength in growth visibility and the royalty portfolio pipeline.Recent updates
Narrative Update • Sep 03
RPRX: Royalty Deals And Buybacks Will Support Future Defensive Cash Flows
Royalty Pharma's analyst price target has been revised from $59.25 to $64.75 as analysts factor in updated guidance, recent Q2 outcomes, and expectations that support higher assumed future P/E levels, despite adjustments to growth and margin assumptions. Analyst Commentary Recent Street research on Royalty Pharma reflects a generally constructive tone, with several firms lifting their price targets in response to updated guidance and Q2 outcomes.Seeking Alpha • Aug 26
Royalty Pharma: The Quiet Compounder The Market Is Still Mispricing
Summary Royalty Pharma demonstrates high-quality, cash-generative compounding with durable royalty growth and disciplined capital deployment, supporting a buy rating. RPRX's 2Q26 results highlight 14% Royalty Receipts growth, elite 95% margins, and $728 million operating cash flow, reinforcing the core compounder thesis. Management raised 2026 Portfolio Receipts guidance to $3.4–$3.5 billion, projecting 7–10% royalty growth despite headwinds like Promacta erosion and IRA-related pressure. Valuation remains attractive on cash flow multiples, with embedded pipeline optionality and forward catalysts such as the Cliramitug deal and strategic pipeline expansion. Read the full article on Seeking AlphaNarrative Update • Aug 19
RPRX: Raised 2026 Guidance And Royalty Pipeline Will Support Long Term Upside
Royalty Pharma's analyst fair value estimate has shifted from $66.00 to $70.00. This reflects updated views from analysts who recently raised price targets in response to Q2 updates, revised 2026 guidance, and perceived strength in growth visibility and the royalty portfolio pipeline.
Narrative Update • Aug 04
RPRX: New Royalty Deal And Buybacks Will Test Earnings Resilience
Analysts have lifted their Royalty Pharma price target by about $10 to $58. This reflects updated views on its revenue growth outlook, profit margins and future P/E assumptions.Narrative Update • Jul 03
RPRX: Royalty Deals And Buybacks Will Test Rich Earnings Assumptions
Royalty Pharma's analyst price target has shifted modestly higher, with updated fair value estimates moving from $46.00 to about $47.90 as analysts factor in revised assumptions around revenue growth, profit margins, and future P/E expectations. Analyst Commentary on Royalty Pharma Recent Street research on Royalty Pharma points to a more cautious tone beneath the modestly higher fair value estimates.Narrative Update • Jun 19
RPRX: Royalty Deals And Buybacks Will Support Long Term Stock Upside
Analysts have raised their price target for Royalty Pharma stock to $66.00 from $60.61, citing updated views on fair value, discount rate, expected revenue growth, profit margins, and future P/E assumptions. Analyst Commentary Recent Street research on Royalty Pharma points to a cluster of higher price targets and supportive commentary around valuation, execution, and growth prospects.Narrative Update • Jun 03
RPRX: Royalty Deals And Buybacks Will Shape Balanced Future Returns
Analysts have lifted their average price target for Royalty Pharma to about $59, up from roughly $52, citing updated views on long term revenue potential, higher expected profitability, and a lower assumed future P/E multiple. These factors are reflected in recent target increases from firms like Morgan Stanley and UBS, as well as positive commentary around the $250m Zymeworks financing deal.Narrative Update • May 02
RPRX: Royalty Deals And Buybacks Will Shape Balanced Forward Outlook
Analysts have raised their blended price target on Royalty Pharma by several dollars to around the mid $40s, citing refined models that factor in slightly higher projected revenue growth, modestly lower profit margins, and continued benefits from recent royalty and financing deals such as the $250m Zymeworks agreement. Analyst Commentary Recent research on Royalty Pharma centers on how the updated price targets line up with the company’s deal pipeline, especially the $250m Zymeworks transaction.Narrative Update • Apr 17
RPRX: Diversified Royalty Portfolio And Recent Deals Will Support Future Upside
Analysts have nudged their price targets for Royalty Pharma modestly higher, with the average fair value estimate moving from about $59.28 to $60.61. They point to the company's diversified royalty portfolio, favorable deal terms such as the $250m Zymeworks financing, and the broader growth of the biopharma royalty market.Narrative Update • Apr 03
RPRX: Royalty Deals And Dividend Policy Will Shape Balanced Forward Outlook
Analysts have raised the fair value estimate for Royalty Pharma to $46.00 from $40.86, citing updated models that reflect perceived strengths in its biopharma royalty exposure, portfolio diversification, and recent deal activity. Analyst Commentary Recent Street research around Royalty Pharma highlights both constructive and cautious views, giving you a mixed picture of how professionals are thinking about the stock.Narrative Update • Mar 19
RPRX: Royalty Deals And Buybacks Will Support Future Upside
Analysts have lifted their price target on Royalty Pharma to $51.56 from $51.00, citing updated Street views on its biopharma royalty exposure and recent deal activity as key supports for the revised fair value estimate. Analyst Commentary Recent Street commentary on Royalty Pharma highlights a mix of optimism around its royalty portfolio and business model, alongside some areas where investors may want to stay cautious on execution and deal risk.Narrative Update • Mar 05
RPRX: Royalty Platform And Portfolio Diversification Will Drive Future Upside Potential
Analysts have nudged their targets higher on Royalty Pharma, with the consensus fair value estimate moving from $56.00 to about $59.28. They cite expectations for the company to benefit from growth in the biopharma royalty market, differentiation from competitors, and a more diversified portfolio.Narrative Update • Feb 19
RPRX: Higher P/E Expectations And Buybacks Will Support Future Upside
Analysts have lifted their average price target on Royalty Pharma from about $46 to roughly $51, citing updated assumptions for fair value, discount rate, growth, margins, and a higher future P/E multiple as key drivers behind the move. Analyst Commentary Recent research coverage on Royalty Pharma has centered on refreshed models for fair value and updated assumptions around discount rates, growth, margins, and future P/E multiples.Analysis Article • Feb 11
Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.235
Royalty Pharma plc's ( NASDAQ:RPRX ) dividend will be increasing from last year's payment of the same period to $0.235...Narrative Update • Feb 05
RPRX: Pending XenoTherapeutics Deal And Dividend Increase Will Shape Near-Term Returns
Analysts have raised their price targets on Royalty Pharma by about $2 to an updated fair value of US$40.86, citing slightly higher long term revenue growth assumptions, a modestly higher future P/E multiple, and largely unchanged discount rate and profit margin inputs. Analyst Commentary Recent research on Royalty Pharma has been mixed, with some firms updating ratings and price targets around the company’s agreed acquisition by XenoTherapeutics at an estimated US$1.82 per share.Analysis Article • Jan 22
Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's
Royalty Pharma plc's ( NASDAQ:RPRX ) dividend will be increasing from last year's payment of the same period to $0.235...Narrative Update • Jan 21
RPRX: Pending XenoTherapeutics Deal And Hold Downgrade Will Limit Near-Term Upside
Analysts have trimmed their price expectations for Royalty Pharma, citing a revised fair value of $38.00 per share. This reflects updated views on revenue growth, profit margins, and future P/E multiples following the announced acquisition by XenoTherapeutics and the recent downgrade to Hold.Narrative Update • Jan 07
RPRX: Agreed XenoTherapeutics Deal Will Highlight Upside In Royalty Portfolio Earnings Power
Analysts have nudged their fair value target for Royalty Pharma up to US$56.00 from US$55.00. This reflects updated assumptions on slower revenue growth, higher margins and a lower future P/E, while also factoring in the recent downgrade to Hold following the agreed acquisition by XenoTherapeutics at an estimated US$1.82 per share.Narrative Update • Dec 15
RPRX Pending XenoTherapeutics Deal Will Anchor Shares Near Buyout Price
Analysts have nudged their price target on Royalty Pharma up by $1, to $38. This reflects modestly stronger revenue growth assumptions, offset by a slightly higher discount rate and lower projected profit margins, and incorporates the limited upside they see given the pending acquisition by XenoTherapeutics.Narrative Update • Dec 01
RPRX: Share Buybacks Will Drive Value Upon Acquisition Completion
Analysts have revised Royalty Pharma's price target slightly upward from $45.54 to $45.98. They note that the pending acquisition by XenoTherapeutics has reduced uncertainty around the company’s valuation.Narrative Update • Nov 17
RPRX: Share Buybacks And Acquisition Will Drive Outperformance After Downgrade
Analysts have raised Royalty Pharma's price target from $44.10 to $45.54, reflecting updated expectations for revenue growth. However, profit margins are anticipated to decrease following recent acquisition developments.Narrative Update • Nov 02
RPRX: Upcoming Licensing Deals And Share Buybacks Will Drive Long-Term Upside
Narrative Update on Royalty Pharma: Analyst Price Target Revision Analysts have lowered their fair value estimate for Royalty Pharma from $44.86 to $44.10 per share. This revision is based on updated modeling of revenue growth and profit margins.Narrative Update • Sep 04
Emerging Therapies And Licensing Will Expand Royalty Opportunities
Analysts maintain a positive outlook for Royalty Pharma, citing resilience amid sector underperformance, limited exposure to policy and macroeconomic risks, and anticipated seasonal strength, with the consensus price target unchanged at $43.27. Analyst Commentary Bullish analysts expect Q2 to be seasonally strong for large biopharma companies, supporting near-term performance.Shareholder Returns
| RPRX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -8.4% | -3.4% | -0.9% |
| 1Y | 61.2% | 44.7% | 14.2% |
Return vs Industry: RPRX exceeded the US Pharmaceuticals industry which returned 44.7% over the past year.
Return vs Market: RPRX exceeded the US Market which returned 14.1% over the past year.
Price Volatility
| RPRX volatility | |
|---|---|
| RPRX Average Weekly Movement | 3.8% |
| Pharmaceuticals Industry Average Movement | 8.6% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: RPRX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: RPRX's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 100 | Pablo Legorreta | www.royaltypharma.com |
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases.
Royalty Pharma plc Fundamentals Summary
| RPRX fundamental statistics | |
|---|---|
| Market cap | US$33.70b |
| Earnings (TTM) | US$811.99m |
| Revenue (TTM) | US$2.54b |
32.1x
P/E Ratio10.3x
P/S RatioIs RPRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RPRX income statement (TTM) | |
|---|---|
| Revenue | US$2.54b |
| Cost of Revenue | US$105.97m |
| Gross Profit | US$2.43b |
| Other Expenses | US$1.62b |
| Earnings | US$811.99m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.82 |
| Gross Margin | 95.82% |
| Net Profit Margin | 32.02% |
| Debt/Equity Ratio | 91.6% |
How did RPRX perform over the long term?
See historical performance and comparisonDividends
1.6%
Current Dividend Yield49%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/13 21:44 |
| End of Day Share Price | 2026/09/11 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Royalty Pharma plc is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Geoffrey Meacham | Citigroup Inc |
| Prem Chulaki | CrispIdea |